C-Reactive Protein and Neutrophil/Lymphocytes Ratio: Prognostic Indicator for Doubling Overall Survival Prediction in Pancreatic Cancer Patients
Abstract
:1. Introduction
2. Materials and Methods
2.1. Patient Selection and Data Acquisition
2.2. Statistics
3. Results
3.1. Patient Characteristics
3.2. Treatment
3.3. Prognostic Factor Analyses
4. Discussion
5. Main Message
Supplementary Materials
Author Contributions
Funding
Conflicts of Interest
References
- Miller, K.D.; Nogueira, L.; Mariotto, A.B.; Rowland, J.H.; Yabroff, K.R.; Alfano, C.M.; Jemal, A.; Kramer, J.L.; Siegel, R.L. Cancer treatment and survivorshio statistics, 2019. CA Cancer J. Clin. 2019, 69, 363–385. [Google Scholar] [CrossRef] [PubMed]
- Sharma, C.; Eltawil, K.M.; Renfrew, P.D.; Walsh, M.J.; Molinari, M. Advances in diagnosis, treatment and palliation of pancreatic carcinoma: 1990–2010. World J. Gastroenterol. 2011, 17, 867–897. [Google Scholar] [CrossRef] [PubMed]
- Rahib, L.; Smith, B.D.; Aizenberg, R.; Rosenzweig, A.B.; Fleshman, J.M.; Matrisian, L.M. Projecting Cancer Incidence and Deaths to 2030: The Unexpected Burden of Thyroid, Liver, and Pancreas Cancers in the United States. Cancer Res. 2014, 74, 2913–2921. [Google Scholar] [CrossRef] [PubMed][Green Version]
- Niederhuber, J.E.; Brennan, M.F.; Menck, H.R. The national cancer data base report on pancreatic cancer. Cancer 1995, 76, 1671–1677. [Google Scholar] [CrossRef]
- Onoe, S.; Maeda, A.; Takayama, Y.; Fukami, Y.; Takahashi, T.; Uji, M.; Kaneoka, Y. The Prognostic Impact of the Lymphocyte-to-Monocyte Ratio in Resected Pancreatic Head Adenocarcinoma. Med. Princ. Pr. 2019. [Google Scholar] [CrossRef]
- Bradley, A.; Van Der Meer, R.; McKay, C.J. A systematic review of methodological quality of model development studies predicting prognostic outcome for resectable pancreatic cancer. BMJ Open 2019, 9, e027192. [Google Scholar] [CrossRef][Green Version]
- Gargiulo, P.; Dietrich, D.; Herrmann, R.; Bodoky, G.; Ruhstaller, T.; Scheithauer, W.; Glimelius, B.; Berardi, S.; Pignata, S.; Brauchli, P. Predicting mortality and adverse events in patients with advanced pancreatic cancer treated with palliative gemcitabine-based chemotherapy in a multicentre phase III randomized clinical trial: The APC-SAKK risk scores. Ther. Adv. Med. Oncol. 2019, 11, 1758835918818351. [Google Scholar] [CrossRef]
- Shimizu, T.; Taniguchi, K.; Asakuma, M.; Tomioka, A.; Inoue, Y.; Komeda, K.; Hirokawa, F.; Uchiyama, K. Lymphocyte-to-Monocyte Ratio and Prognostic Nutritional Index Predict Poor Prognosis in Patients on Chemotherapy for Unresectable Pancreatic Cancer. Anticancer. Res. 2019, 39, 2169–2176. [Google Scholar] [CrossRef]
- Bhatti, I.; Peacock, O.; Lloyd, G.; Larvin, M.; Hall, R.I. Preoperative hematologic markers as independent predictors of prognosis in resected pancreatic ductal adenocarcinoma: Neutrophil-lymphocyte versus platelet-lymphocyte ratio. Am. J. Surg. 2010, 200, 197–203. [Google Scholar] [CrossRef]
- Kim, W.; Lim, T.; Park, P.; Choi, S.; Kim, W. Prognostic impact of the combination of the neutrophil-to-lymphocyte ratio and serum carbohydrate antigen 19-9 in patients with pancreas head cancer. ANZ J. Surg. 2019, 89, E302–E307. [Google Scholar] [CrossRef]
- Galizia, G.; Lieto, E.; Zamboli, A.; De Vita, F.; Castellano, P.; Romano, C.; Auricchio, A.; Cardella, F.; De Stefano, L.; Orditura, M. Neutrophil to lymphocyte ratio is a strong predictor of tumor recurrence in early colon cancers: A propensity score-matched analysis. Surgery 2015, 158, 112–120. [Google Scholar] [CrossRef] [PubMed]
- Bailey, P.; Initiative, A.P.C.G.; Chang, D.K.; Nones, K.; Johns, A.L.; Patch, A.-M.; Gingras, M.-C.; Miller, D.K.; Christ, A.N.; Bruxner, T.J.C.; et al. Genomic analyses identify molecular subtypes of pancreatic cancer. Nature 2016, 531, 47–52. [Google Scholar] [CrossRef] [PubMed]
- Szkandera, J.; Stotz, M.; Absenger, G.; Stojakovic, T.; Samonigg, H.; Kornprat, P.; Schaberl-Moser, R.; Alzoughbi, W.; Lackner, C.; Ress, A.L.; et al. Validation of C-reactive protein levels as a prognostic indicator for survival in a large cohort of pancreatic cancer patients. Br. J. Cancer 2014, 110, 183–188. [Google Scholar] [CrossRef] [PubMed]
- Seimiya, T.; Otsuka, M.; Iwata, T.; Tanaka, E.; Suzuki, T.; Sekiba, K.; Yamagami, M.; Ishibashi, R.; Koike, K. Inflammation and de-differentiation in pancreatic carcinogenesis. World J. Clin. Cases 2018, 6, 882–891. [Google Scholar] [CrossRef]
- Szkandera, J.; Stotz, M.; Eisner, F.; Absenger, G.; Stojakovic, T.; Samonigg, H.; Kornprat, P.; Schaberl-Moser, R.; Alzoughbi, W.; Ress, A.L.; et al. External Validation of the Derived Neutrophil to Lymphocyte Ratio as a Prognostic Marker on a Large Cohort of Pancreatic Cancer Patients. PLoS ONE 2013, 8, e78225. [Google Scholar] [CrossRef]
- Lohr, M.; Klöppel, G.; Maisonneuve, P.; Lowenfels, A.B.; Lüttges, J. Frequency of K-ras Mutations in Pancreatic Intraductal Neoplasias Associated with Pancreatic Ductal Adenocarcinoma and Chronic Pancreatitis: A Meta-Analysis1. Neoplasia 2005, 7, 17–23. [Google Scholar] [CrossRef]
- Tranum, B.L.; Haut, A. Thrombocytosis: Platelet kinetics in neoplasia. J. Lab. Clin. Med. 1974, 84, 615–619. [Google Scholar]
- Goubran, H.A.; Burnouf, T.; Radosevic, M.; El-Ekiaby, M. The platelet–cancer loop. Eur. J. Intern. Med. 2013, 24, 393–400. [Google Scholar] [CrossRef]
- Picon-Ruiz, M.; Morata-Tarifa, C.; Valle-Goffin, J.J.; Friedman, E.R.; Slingerland, J.M. Obesity and adverse breast cancer risk and outcome: Mechanistic insights and strategies for intervention. CA Cancer J. Clin. 2017, 67, 378–397. [Google Scholar] [CrossRef]
- Engin, A. The Definition and Prevalence of Obesity and Metabolic Syndrome. Obes. Lipotoxicity 2017, 960, 1–17. [Google Scholar] [CrossRef]
- Ackerman, S.E.; Blackburn, O.A.; Marchildon, F.; Cohen, P. Insights into the Link Between Obesity and Cancer. Curr. Obes. Rep. 2017, 6, 195–203. [Google Scholar] [CrossRef] [PubMed]
- Jiang, Q.-L.; Wang, C.-F.; Tian, Y.-T.; Huang, H.; Zhang, S.-S.; Zhao, D.-B.; Ma, J.; Yuan, W.; Sun, Y.-M.; Che, X.; et al. Body mass index does not affect the survival of pancreatic cancer patients. World J. Gastroenterol. 2017, 23, 6287–6293. [Google Scholar] [CrossRef] [PubMed][Green Version]
- Howard, R.; Scheiner, A.; Kanetsky, P.A.; Egan, K.M. Sociodemographic and lifestyle factors associated with the neutrophil-to-lymphocyte ratio. Ann. Epidemiol. 2019, 38, 11–21.e6. [Google Scholar] [CrossRef] [PubMed]
- Tu, X.; Wang, F.; Chang, T.; Zhang, C.; Zhang, M.; Liu, Z.; Qiu, S.; Yang, L.; Wei, Q. Predictive value of preoperative neutrophil-to-lymphocyte ratio in non-metastatic papillary renal cell carcinoma patients after receiving curative surgery. Cancer Manag. Res. 2019, 11, 7515–7524. [Google Scholar] [CrossRef] [PubMed]
- Zhang, B.; Du, W.; Gan, K.; Fang, Q.; Zhang, X.; Kang, G. Significance of the neutrophil-to-lymphocyte ratio in young patients with oral squamous cell carcinoma. Cancer Manag. Res. 2019, 11, 7597–7603. [Google Scholar] [CrossRef] [PubMed]
- Rao, J.S.; Hanumappa, H.K.; Joseph, E.P.; Chowdappa, R.G.; Ramesh, R. Elevated Neutrophil–Lymphocyte Ratio in Luminal-Type Locally Advanced Breast Cancer to Circumvent Neo-Adjuvant Chemotherapy. Indian J. Surg. Oncol. 2019, 10, 454–459. [Google Scholar] [CrossRef] [PubMed]
- Karamitopoulou, E. Tumour microenvironment of pancreatic cancer: Immune landscape is dictated by molecular and histopathological features. Br. J. Cancer 2019, 121, 5–14. [Google Scholar] [CrossRef] [PubMed]
- Stone, M.L.; Beatty, G.L. Cellular determinants and therapeutic implications of inflammation in pancreatic cancer. Pharmacol. Ther. 2019, 201, 202–213. [Google Scholar] [CrossRef]
Characteristic | Score (N = 240) |
---|---|
Age—no. of years | |
Median | 67 |
Range | 29–90 |
Sex—no. (%) | |
Male | 114 (48%) |
Female | 126 (52%) |
Tumor stage at diagnosis—no. (%) | |
Locally advanced | 56 (23.3%) |
Metastatic | 184 (76.7%) |
Palliative 1st line protocol—no. (%) | |
FOLFIRINOX: | 102 (42.5%) |
Gemcitabine/Nab-Paclitaxel | 31(12.9%) |
Gemcitabine | 51 (21%) |
GEMOX | 41 (17%) |
Other | 15 (6.2%) |
Chemotherapy beyond 1st line protocol—no. (%) | |
2nd line palliative chemotherapy | 138 (57.7%) |
3rd line palliative chemotherapy | 66 (27.5%) |
Variable (above ULN) | Univariate | Multivariate | |||||
---|---|---|---|---|---|---|---|
HR (95% CI) | P (1) | n | HR (95% CI) | P (1) | n | ||
Gender | Male vs. Female | 0.78 (0.6–1) | 0.06 | 240 | na | ||
CEA | >3.5 mcg/L | 1.45 (1–1.9) | 0.02 | 206 | 1.4 (0.9–2.1) | 0.1 | 206 |
CA19-9 | >37 U/mL | 1.2 (0.7–1.8) | 0.3 | 220 | na | ||
CRP | >0.6 mg/dL | 1.7 (1.3–2.1) | <0.001 | 204 | 1.5 (1–2.1) | 0.026 | 204 |
Leucocytes | >10 G/L | 1.57 (1–2.1) | <0.006 | 236 | 1.4 (0.9–2.1) | 1.1 | 236 |
Neutrophils | >7 G/L | 1.7 (1.2–2.6) | 0.003 | 171 | 1.3 (0.7–2) | 0.8 | 171 |
Monocytes | >1 G/L | 1.8 (1–3.2) | <0.039 | 171 | 1.2 (0.8–1.9) | 0.2 | 171 |
NLR | >6 (ROC) | 1.7 (1.2–2.4) | <0.001 | 171 | 1.7 (1.2–2.6) | 0.003 | 171 |
LMR | >3.98 (ROC) | 0.6 (0.4–0.8) | 0.01 | 171 | 1.4 (0.9–2.1) | 1.1 | 171 |
Plt/LR | >333 (ROC) | 1.1 (0.7–1.7) | 0.5 | 171 | 1.6 (1.–2.6) | 0.2 | 171 |
Platelets | >400 G/L | 1 (0.6–1.6) | 0.9 | 236 | na |
© 2019 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/).
Share and Cite
Schlick, K.; Magnes, T.; Huemer, F.; Ratzinger, L.; Weiss, L.; Pichler, M.; Melchardt, T.; Greil, R.; Egle, A. C-Reactive Protein and Neutrophil/Lymphocytes Ratio: Prognostic Indicator for Doubling Overall Survival Prediction in Pancreatic Cancer Patients. J. Clin. Med. 2019, 8, 1791. https://doi.org/10.3390/jcm8111791
Schlick K, Magnes T, Huemer F, Ratzinger L, Weiss L, Pichler M, Melchardt T, Greil R, Egle A. C-Reactive Protein and Neutrophil/Lymphocytes Ratio: Prognostic Indicator for Doubling Overall Survival Prediction in Pancreatic Cancer Patients. Journal of Clinical Medicine. 2019; 8(11):1791. https://doi.org/10.3390/jcm8111791
Chicago/Turabian StyleSchlick, Konstantin, Teresa Magnes, Florian Huemer, Lukas Ratzinger, Lukas Weiss, Martin Pichler, Thomas Melchardt, Richard Greil, and Alexander Egle. 2019. "C-Reactive Protein and Neutrophil/Lymphocytes Ratio: Prognostic Indicator for Doubling Overall Survival Prediction in Pancreatic Cancer Patients" Journal of Clinical Medicine 8, no. 11: 1791. https://doi.org/10.3390/jcm8111791